Meropenem

meropenem

1
美罗培南
在EPIC试验中，与美罗培南（meropenem）相比，plazomicin成功达到了美国FDA规定的非劣效性的主要疗效终点，并取得了欧洲药品管理局（EMA）指定的优越性的主要疗效终点。
2
美洛培南
美洛培南(Meropenem)是第一个应用于临床的1.B甲基碳青霉烯类抗生素。其体外具有广谱抗革兰阳性和阴性菌作用,包括绿脓杆菌和厌氧菌。
3
配能
美洛配能 (Meropenem )为碳青霉烯类抗生素 ,是一种广谱的β―内酰胺抗菌素 ..

短语

1
Aim To synthesize meropenem trihydrate, a carbapenem antibiotic.
目的合成碳青霉烯类抗生素美罗培南。
2
Objective To evaluate the efficacy of meropenem in moderate to severe bacterial infection.
目的观察美罗培南治疗中、重度细菌感染的有效性。
3
OBJECTIVE To evaluate the efficacy and safety of meropenem on the treatment of hospital acquired infection.
目的评价美罗培南治疗医院感染的临床疗效和安全性。

Meropenem
Meropenem is an ultra-broad-spectrum injectable antibiotic used to treat a wide variety of infections. It is a β-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Dainippon Sumitomo Pharma. It gained US FDA approval in July 1996. It penetrates well into many tissues and body fluids, including cerebrospinal fluid, bile, heart valve, lung, and peritoneal fluid. It was initially marketed by AstraZeneca under the trade name Merrem, and is now available in many countries as a generic.

点击反馈